Attgeno has announced that Björn Westberg has been appointed CFO and member of the management team at Attgeno.
Westberg most recently comes from a role as CFO at Enea. He has extensive experience in the life science sector, where he has been active for 24 years in both small biotech and global pharmaceutical companies, states the company.
“I am very proud and happy to have been able to tie Björn to Attgeno. Through his solid background and international experience in Life Science, Attgeno receives an important contribution to further development into a successful pharmaceutical company. The Board and I both look forward to the continued work with Björn, which includes developing the company so that Attgeno’s organization meets the requirements for listed companies, as a public listing is an alternative that may be relevant in the upcoming years,” says Per Agvald, Attgeno’s co-founder and CEO.
Assignments in Nasdaq-listed companies
In his previous roles as CFO, Westberg has had four assignments in Nasdaq-listed companies, including Recipharm and Bonesupport, and has also led projects for listing on Nasdaq Stockholm. His responsibilities in previous roles include finance, financing, investor relations, legal affairs, strategy development, HR and IT.
Björn Westberg will take up the role of CFO in Attgeno in September 2021.
Photo of Björn Westberg: Attgeno